Transdermal Skin Patches Market Report 2025

The transdermal skin patches market size has grown steadily in recent years. It will grow from $7.46 billion in 2024 to $7.72 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, strong economic growth in emerging markets, the increase in pharmaceutical r&d expenditure and increased healthcare expenditure.

The transdermal skin patches market size is expected to see steady growth in the next few years. It will grow to $9.36 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to the increase in smoking cessation, the rapid growth in the aging population, the increasing healthcare expenditure and the increase in cardiovascular diseases. Major trends in the forecast period include technological advancement in transdermal skin patches, advancements in diabetes transdermal patches, robust research and development activities, product innovation, collaborations and partnerships, wearable skin patches, advancements in microneedle patches for vaccination and new iontophoresis patches.

The rising incidence of cardiovascular disease is anticipated to drive the growth of the transdermal skin patches market in the future. Cardiovascular diseases affect the heart and blood vessels and are often associated with the buildup of fatty deposits in the arteries (atherosclerosis) and an increased risk of blood clots. Transdermal skin patches are utilized to prevent angina (chest pain) in individuals with coronary artery disease, characterized by narrowed blood vessels supplying the heart. They also enhance bioavailability in the treatment of heart failure. For instance, in August 2022, a report from the American College of Cardiology, a U.S.-based non-profit medical association, projected that all four cardiovascular risk factors in the United States would rise between 2025 and 2060. The most significant increase is expected in diabetes, with a 39.3% rise to 55 million individuals, followed by dyslipidemia (up 27.6% to 126 million), hypertension (up 25.1% to 162 million), and obesity (up 18.3% to 126 million). The research also indicated that the most substantial projected increases in cardiovascular disease rates would be for stroke (up 33.8% to 15 million) and heart failure (up 33.4% to 13 million), along with ischemic heart disease (up 30.7% to 29 million) and heart attack (up 16.9% to 16 million). Consequently, the growing prevalence of cardiovascular disease is propelling the expansion of the transdermal skin patches market.

The growth of the transdermal skin patches market is significantly influenced by advancements in modern technologies. These technological advances are expanding the range of drugs that can be delivered transdermally, encompassing small molecule hydrophobic drugs, hydrophilic drugs, and macromolecules. The enhanced technological capabilities contribute to increased efficiency and the broader adoption of transdermal drug delivery systems (TDDS), consequently elevating the popularity and demand for TDDS. For instance, in September 2022, Corium, a biopharmaceutical company based in the United States, introduced Adlarity, a transdermal patch designed for Alzheimer's treatment. Utilizing the unique Corplex technology, Adlarity provides controlled and sustained release of donepezil, benefiting individuals with Alzheimer's-related dementia across various severity levels.

Leading companies in the transdermal skin patches market are intensifying their focus on introducing innovative products and securing approvals to establish a competitive advantage. Innovative products refer to novel or improved solutions addressing existing problems or needs, such as drugs or medical devices. In March 2022, Noven Pharmaceuticals Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for XELSTRY (dextroamphetamine) transdermal system. This marked the first and only approved amphetamine patch for treating ADHD (Attention-Deficit or Hyperactivity Disorder). XELSTRYM, intended for use two hours before the required effect, provides sustained release for nine hours, allowing for personalized dosages based on clinical response and tolerability.

Major companies in the transdermal skin patches market are increasingly pursuing acquisitions and collaborations to strengthen and broaden their presence for market growth. These strategic mergers and acquisitions, along with collaborations, enable companies to leverage new technologies, helping them gain a competitive edge. For example, in August 2022, LTS LOHMANN Therapie-Systeme AG, a Germany-based firm specializing in medical adhesive technologies, acquired Tapemark Inc. for an undisclosed amount. This acquisition allows Tapemark’s St. Paul facility to integrate into LTS’s global operations network, complementing LTS's existing facilities in Germany and West Caldwell, NJ, in the U.S. Tapemark Inc. is a U.S.-based manufacturer of transdermal skin patches used for delivering medications through the skin.

In January 2022, Cumberland Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical company, acquired Sancuso, a granisetron transdermal patch, from Kyowa Kirin for $13.5 million. This transaction granted Cumberland the U.S. rights to SANCUSO, enabling full control over its commercial aspects, including marketing, distribution, manufacturing, and medical support. SANCUSO, developed by Kyowa Kirin, is a transdermal patch delivering granisetron, a serotonin-3 (5-HT3) receptor antagonist, to prevent chemotherapy-induced nausea and vomiting (CINV).

Major companies operating in the transdermal skin patches market include Novartis, Hisamitsu Pharmaceutical Co., Inc, Henan Lingrui Pharmaceutical, Teva Pharmaceuticals, Luye Pharma Group Ltd, Purdue Pharma L.P., Nitto Denko Corporation, AdhexPharma, Noven Pharmaceuticals, Teikoku Pharma, Mylan Pharmaceuticals Inc, 3M Company, Acrux Ltd, Access Pharmaceuticals Inc, Rusan Pharma, Glenmark Pharmaceuticals, Cipla Ltd, Mundipharma, Dr Reddy’s Laboratories, Chattem, Clarity Medical, Welcare Industries S.P. A, F.L. Medical S.r.l, Europlaz Technologies Ltd, Zentiva, Medical-Łomża Sp. z o.o., Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Endo Pharmaceuticals Inc.

North America was the largest region in the global transdermal skin patches market in 2024. Middle East is expected to be the fastest growing region in the transdermal skin patches market report during the forecast period. The regions covered in the transdermal skin patches market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transdermal skin patches market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Transdermal skin patches represent a drug delivery method wherein a predetermined dose of medication is administered through an adhesive patch, absorbing into the bloodstream via the skin. These patches offer a precise and predetermined dosage of medication, facilitating absorption through the skin into the bloodstream.

The primary categories within the transdermal skin patches market include fentanyl transdermal patches, nicotine transdermal patches, buprenorphine transdermal patches, clonidine transdermal patches, oxybutynin transdermal patches, and others. Nicotine transdermal skin patches are designed to aid individuals in quitting smoking by providing a controlled source of nicotine through the skin, helping alleviate withdrawal symptoms associated with smoking cessation. Various products in this market utilize matrix, drugs in the adhesive, reservoir, and vapor technologies, catering to applications such as pain relief, nicotine cessation, hormone replacement therapy, as well as addressing neurological and cardiovascular disorders, among others.

The transdermal skin patches market research report is one of a series of new reports that provides transdermal skin patches market statistics, including transdermal skin patches industry global market size, regional shares, competitors with a transdermal skin patches market share, detailed transdermal skin patches market segments, market trends and opportunities, and any further data you may need to thrive in the transdermal skin patches industry. This transdermal skin patches market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transdermal skin patches market consists of sales of single-layer drug-in-adhesive, multi-layer drug-in-adhesive, and vapor patch. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.